June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
159 citations
,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
130 citations
,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
July 2021 in “British Journal of Dermatology” A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
August 2022 in “Revista de la Universidad Industrial de Santander/Salud UIS” Stress-related hair loss was reversed with a special medication.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
February 2026 in “Colloids and Surfaces A Physicochemical and Engineering Aspects” JAK inhibitors can enter the skin through hair follicles using a unique pathway.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
144 citations
,
September 2012 in “Genes & development” Aging causes skin stem cells to work less effectively.